Expression of protease-activated receptors on platelets in healthy individuals

doi:10.1007/s11684-009-0040-7

Front Med Chin

2009, Vol. 3

Issue (2) : 236-239 https://doi.org/10.1007/s11684-009-0040-7

RESEARCH ARTICLE

Expression of protease-activated receptors on platelets in healthy individuals

Rui ZHU, Lin SHEN(

)

Department of Integrated Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

Download: PDF(92 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

This study aimed to investigate the expression of protease-activated receptors (PARs) on platelets in healthy individuals and preliminarily elucidate physiological functions of PARs. Thirty healthy volunteers, who did not take any anticoagulants and antiplatelet agents within 10 days before the examination, were recruited. Fasting venous blood (5 mL) was taken from the medial cubital vein in each individual and platelet-rich plasma (PRP) was prepared. The expression of PAR1 mRNA and PAR4 mRNA in PRP was determined by RT-PCR analysis. The results showed that the average levels of PAR1 mRNA and PAR4 mRNA on platelets in healthy individuals were 0.1601 ± 0.0269 and 0.1073 ± 0.0194 respectively. In combination with literature analysis, it was concluded that the thrombin signaling pathway plays a vital role in the development of hemostasis and thrombosis, and the selective PARs antagonist has the potential for extensive application in clinical practice.

Keywords protease-activated receptors platelet

Corresponding Author(s): SHEN Lin,Email:shenlinhb@yahoo.com.cn

Issue Date: 05 June 2009

Cite this article:

Rui ZHU,Lin SHEN. Expression of protease-activated receptors on platelets in healthy individuals[J]. Front Med Chin, 2009, 3(2): 236-239.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-009-0040-7
https://academic.hep.com.cn/fmd/EN/Y2009/V3/I2/236

Tab.1 Gene-specific primer sequences used in conventional PCR amplifications

Fig.1 The expression of PARs mRNA on platelets in healthy individuals. (a) β-active mRNA; (b) PAR1 mRNA; (c) PAR4 mRNA.

1	Ruggeri Z M. Platelets in atherothrombosis. Nat Med , 2002, 8(11): 1227-1234 doi: 10.1038/nm1102-1227
2	Kahn M L, Zheng Y W, Huang W, Bigornia V, Zeng D, Moff S, Farese R V Jr, Tam C, Coughlin S R. A dual thrombin receptor system for platelet activation. Nature , 1998, 394(6694): 690-694 doi: 10.1038/29325
3	Coughlin S R. How the protease thrombin talks to cells. Proc Natl Acad Sci USA , 1999, 96(20): 11023-11027 doi: 10.1073/pnas.96.20.11023
4	Macfarlane S R, Seatter M J, Kanke T, Hunter G D, Plevin R. Proteinase-activated receptors. Pharmacol Rev , 2001, 53(2): 245-282
5	Faruqi T R, Weiss E J, Shapiro M J, Huang W, Coughlin S R. Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function. J Biol Chem , 2000, 275(26): 19728-19734 doi: 10.1074/jbc.M909960199
6	Hamilton J R, Frauman A G, Cocks T M. Increased expression of protease-activated receptor-2 (PAR2) and PAR4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to PAR2 and PAR4 agonists. Circ Res , 2001, 89(1): 92-98 doi: 10.1161/hh1301.092661
7	Coughlin S R. Thrombin signalling and protease-activated receptors. Nature , 2000, 407(6801): 258-264 doi: 10.1038/35025229
8	Kahn M L, Nakanishi-Matsui M, Shapiro M J, Ishihara H, Coughlin S R. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest , 1999, 103(6): 879-887 doi: 10.1172/JCI6042
9	Vu T K, Hung D T, Wheaton V I, Coughlin S R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell , 1991, 64(6): 1057-1068 doi: 10.1016/0092-8674(91)90261-V
10	Chen J, Ishii M, Wang L, Ishii K, Coughlin S R. Thrombin receptor activation: confirmation of the intramolecular tethered liganding hypothesis and discovery of an alternative liganding mode. J Biol Chem , 1994, 269(23): 16041-16045
11	Reed G L. Platelet secretory mechanisms. Semin Thromb Hemost , 2004, 30(4): 441-450 doi: 10.1055/s-2004-833479
12	Dorsam R T, Kunapuli S P. Central role of the P2Y12 receptor in platelet activation. J Clin Invest , 2004, 113(3): 340-345
13	Cook J J, Sitko G R, Bednar B, Condra C, Mellott M J, Feng D M, Nutt R F, Shafer J A, Gould R J, Connolly T M. An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation , 1995, 91(12): 2961-2971
14	Sambrano G R, Weiss E J, Zheng Y W, Huang W, Coughlin S R. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature , 2001, 413(6851): 74-78 doi: 10.1038/35092573
15	Pakala R, Liang C T, Benedict C R. Inhibition of arterial thrombosis by a peptide ligand of the thrombin receptor. Thromb Res , 2000, 100(1): 89-96 doi: 10.1016/S0049-3848(00)00307-8
16	Hasan A A, Rebello S S, Smith E, Srikanth S, Werns S, Driscoll E, Faul J, Brenner D, Normolle D, Lucchesi B R, Schmaier A H. Thrombostatin inhibits induced canine coronary thrombosis. Thromb Haemost , 1999, 82(3): 1182-1187
17	Connolly T M, Condra C, Feng D M, Cook J J, Stranieri M T, Reilly C F, Nutt R F, Gould R J. Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides. Thromb Haemost , 1994, 72(4): 627-633
18	Derian C K, Santulli R J, Tomko K A, Haertlein B J, Andrade-Gordon P. Species differences in platelet responses to thrombin and SFLLRN. Receptor-mediated calcium mobilization and aggregation and regulation by protein kinases. Thromb Res , 1995, 78(6): 505-519 doi: 10.1016/0049-3848(95)00084-5
19	Zhang H C, Derian C K, Andrade-Gordon P, Hoekstra W J, McComsey D F, White K B, Poulter B L, Addo M F, Cheung W M, Damiano B P, Oksenberg D, Reynolds E E, Pandey A, Scarborough R M, Maryanoff B E. Discovery and optimization of a novel series of thrombin receptor (par-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates. J Med Chem , 2001, 44(7): 1021-1024 doi: 10.1021/jm000506s
20	Andrade-Gordon P, Derian C K, Maryanoff B E, Zhang H C, Addo M F, Cheung W M, Damiano B P, D'Andrea M R, Darrow A L, de Garavilla L, Eckardt A J, Giardino E C, Haertlein B J, McComsey D F. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J Pharmacol Exp Ther , 2001, 298(1): 34-42
21	Derian C K, Damiano B P, Addo M F, Darrow A L, D'Andrea M R, Nedelman M, Zhang H C, Maryanoff B E, Andrade-Gordon P. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther , 2003, 304(2): 855-861 doi: 10.1124/jpet.102.042663
22	Ahn H S, Foster C, Boykow G, Stamford A, Manna M, Graziano M. Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem Pharmacol , 2000, 60(10): 1425-1434 doi: 10.1016/S0006-2952(00)00460-3

[1]	Wenjing Zhang, Caijun Zha, Xiumin Lu, Ruichun Jia, Fei Gao, Qi Sun, Meili Jin, Yanhong Liu. Anti-β₂GPI/β₂GPI complexes induce platelet activation and promote thrombosis via p38MAPK: a pathway to targeted therapies[J]. Front. Med., 2019, 13(6): 680-689.
[2]	Yinlong Zhang, Guangna Liu, Jingyan Wei, Guangjun Nie. Platelet membrane-based and tumor-associated platelet- targeted drug delivery systems for cancer therapy[J]. Front. Med., 2018, 12(6): 667-677.
[3]	Isabel Andia, Michele Abate. Platelet-rich plasma: combinational treatment modalities for musculoskeletal conditions[J]. Front. Med., 2018, 12(2): 139-152.
[4]	Wenjing Zhang,Fei Gao,Donghe Lu,Na Sun,Xiaoxue Yin,Meili Jin,Yanhong Liu. Anti-β₂ glycoprotein I antibodies in complex with β₂ glycoprotein I induce platelet activation via two receptors: apolipoprotein E receptor 2' and glycoprotein I bα[J]. Front. Med., 2016, 10(1): 76-84.
[5]	Guocheng LIU MD, Shouhua YANG MD, Zehua WANG MD, . The relationship between platelet-derived growth factor expression and angiogenesis/lymphangiogenesis in cervical cancer[J]. Front. Med., 2009, 3(4): 447-451.
[6]	XIA Dasheng, SONG Yanqiu, LI Chao, ZHANG Feng, WEI Minxin. The change of serum leptin and its relationship with platelet membrane glycoprotein Ib in patients with coronary heart disease[J]. Front. Med., 2007, 1(4): 352-355.
[7]	GONG Xiaowei, WEI Jie, LI Yusheng, CHENG Weiwei, DENG Peng, JIANG Yong. Involvement of p38 mitogen-activated protein kinase in the regulation of platelet-derived growth factor -induced cell migration[J]. Front. Med., 2007, 1(3): 248-252.

Viewed

Full text

Abstract

Cited

Shared

Discussed